These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 29928692)
1. X chromosome protects against bladder cancer in females via a Kaneko S; Li X Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692 [TBL] [Abstract][Full Text] [Related]
3. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601 [TBL] [Abstract][Full Text] [Related]
4. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Liu L; Cui J; Zhao Y; Liu X; Chen L; Xia Y; Wang Y; Chen S; Sun S; Shi B; Zou Y Mol Cancer; 2021 May; 20(1):77. PubMed ID: 34006303 [TBL] [Abstract][Full Text] [Related]
5. Significance of KDM6A mutation in bladder cancer immune escape. Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747 [TBL] [Abstract][Full Text] [Related]
6. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125 [TBL] [Abstract][Full Text] [Related]
7. Intravesical delivery of Kong N; Zhang R; Wu G; Sui X; Wang J; Kim NY; Blake S; De D; Xie T; Cao Y; Tao W Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35131941 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells. Terashima M; Ishimura A; Wanna-Udom S; Suzuki T Biochem Biophys Res Commun; 2017 Sep; 490(4):1407-1413. PubMed ID: 28698146 [TBL] [Abstract][Full Text] [Related]
9. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064 [TBL] [Abstract][Full Text] [Related]
10. The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity. Itoh Y; Golden LC; Itoh N; Matsukawa MA; Ren E; Tse V; Arnold AP; Voskuhl RR J Clin Invest; 2019 Aug; 129(9):3852-3863. PubMed ID: 31403472 [TBL] [Abstract][Full Text] [Related]
11. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1. Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637 [TBL] [Abstract][Full Text] [Related]
12. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility. Lee SW; Park DY; Kim MY; Kang C Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835 [TBL] [Abstract][Full Text] [Related]
13. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A. Botrous S; Elmaghraby A; Achy SE; Mustafa Y; Abdel-Rahman S BMC Cancer; 2024 Aug; 24(1):971. PubMed ID: 39118085 [TBL] [Abstract][Full Text] [Related]
14. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. Yang J; Platt LT; Maity B; Ahlers KE; Luo Z; Lin Z; Chakravarti B; Ibeawuchi SR; Askeland RW; Bondaruk J; Czerniak BA; Fisher RA Oncotarget; 2016 Oct; 7(43):69159-69172. PubMed ID: 27713144 [TBL] [Abstract][Full Text] [Related]
15. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer. Qiu H; Makarov V; Bolzenius JK; Halstead A; Parker Y; Wang A; Iyer GV; Wise H; Kim D; Thayaparan V; Lindner DJ; Haber GP; Ting AH; Ren B; Chan TA; Arora V; Solit DB; Lee BH Cancer Res; 2023 Mar; 83(6):814-829. PubMed ID: 36638328 [TBL] [Abstract][Full Text] [Related]
16. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation. Gažová I; Lengeling A; Summers KM Mol Genet Metab; 2019 May; 127(1):31-44. PubMed ID: 31097364 [TBL] [Abstract][Full Text] [Related]
17. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer. Barrows D; Feng L; Carroll TS; Allis CD Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154 [TBL] [Abstract][Full Text] [Related]
18. UTX Mutations in Human Cancer. Wang L; Shilatifard A Cancer Cell; 2019 Feb; 35(2):168-176. PubMed ID: 30753822 [TBL] [Abstract][Full Text] [Related]
19. Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Hurst CD; Alder O; Platt FM; Droop A; Stead LF; Burns JE; Burghel GJ; Jain S; Klimczak LJ; Lindsay H; Roulson JA; Taylor CF; Thygesen H; Cameron AJ; Ridley AJ; Mott HR; Gordenin DA; Knowles MA Cancer Cell; 2017 Nov; 32(5):701-715.e7. PubMed ID: 29136510 [TBL] [Abstract][Full Text] [Related]
20. X chromosome escapee genes are involved in ischemic sexual dimorphism through epigenetic modification of inflammatory signals. Qi S; Al Mamun A; Ngwa C; Romana S; Ritzel R; Arnold AP; McCullough LD; Liu F J Neuroinflammation; 2021 Mar; 18(1):70. PubMed ID: 33712031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]